TY - JOUR
T1 - The transcription factor BACH2 promotes tumor immunosuppression
AU - Roychoudhuri, Rahul
AU - Eil, Robert L.
AU - Clever, David
AU - Klebanoff, Christopher A.
AU - Sukumar, Madhusudhanan
AU - Grant, Francis M.
AU - Yu, Zhiya
AU - Mehta, Gautam
AU - Liu, Hui
AU - Jin, Ping
AU - Ji, Yun
AU - Palmer, Douglas C.
AU - Pan, Jenny H.
AU - Chichura, Anna
AU - Crompton, Joseph G.
AU - Patel, Shashank J.
AU - Stroncek, David
AU - Wang, Ena
AU - Marincola, Francesco M.
AU - Okkenhaug, Klaus
AU - Gattinoni, Luca
AU - Restifo, Nicholas P.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - The immune system has a powerful ability to recognize and kill cancer cells, but its function is often suppressed within tumors, preventing clearance of disease. Functionally diverse innate and adaptive cellular lineages either drive or constrain immune reactions within tumors. The transcription factor (TF) BACH2 regulates the differentiation of multiple innate and adaptive cellular lineages, but its role in controlling tumor immunity has not been elucidated. Here, we demonstrate that BACH2 is required to establish immunosuppression within tumors. Tumor growth was markedly impaired in Bach2-deficient mice and coincided with intratumoral activation of both innate and adaptive immunity. However, augmented tumor clearance in the absence of Bach2 was dependent upon the adaptive immune system. Analysis of tumor-infiltrating lymphocytes from Bach2-deficient mice revealed high frequencies of rapidly proliferating effector CD4+ and CD8+ T cells that expressed the inflammatory cytokine IFN-γ. Effector T cell activation coincided with a reduction in the frequency of intratumoral Foxp3+ Tregs. Mechanistically, BACH2 promoted tumor immunosuppression through Treg-mediated inhibition of intratumoral CD8+ T cells and IFN-γ. These findings demonstrate that BACH2 is a key component of the molecular program of tumor immunosuppression and identify therapeutic targets for the reversal of immunosuppression in cancer.
AB - The immune system has a powerful ability to recognize and kill cancer cells, but its function is often suppressed within tumors, preventing clearance of disease. Functionally diverse innate and adaptive cellular lineages either drive or constrain immune reactions within tumors. The transcription factor (TF) BACH2 regulates the differentiation of multiple innate and adaptive cellular lineages, but its role in controlling tumor immunity has not been elucidated. Here, we demonstrate that BACH2 is required to establish immunosuppression within tumors. Tumor growth was markedly impaired in Bach2-deficient mice and coincided with intratumoral activation of both innate and adaptive immunity. However, augmented tumor clearance in the absence of Bach2 was dependent upon the adaptive immune system. Analysis of tumor-infiltrating lymphocytes from Bach2-deficient mice revealed high frequencies of rapidly proliferating effector CD4+ and CD8+ T cells that expressed the inflammatory cytokine IFN-γ. Effector T cell activation coincided with a reduction in the frequency of intratumoral Foxp3+ Tregs. Mechanistically, BACH2 promoted tumor immunosuppression through Treg-mediated inhibition of intratumoral CD8+ T cells and IFN-γ. These findings demonstrate that BACH2 is a key component of the molecular program of tumor immunosuppression and identify therapeutic targets for the reversal of immunosuppression in cancer.
UR - http://www.scopus.com/inward/record.url?scp=84956901724&partnerID=8YFLogxK
U2 - 10.1172/JCI82884
DO - 10.1172/JCI82884
M3 - Review article
C2 - 26731475
AN - SCOPUS:84956901724
SN - 0021-9738
VL - 126
SP - 599
EP - 604
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 2
ER -